Since its establishment in 2018, the South African Health Products Regulatory Authority (SAHPRA) has implemented a comprehensive regulatory framework designed to protect patients through rigorous oversight of medicines, medical devices, and complementary medicines. Operating under the Medicines and Related Substances Act, SAHPRA combines pre-market registration assessments with robust post-market surveillance systems to ensure product safety and efficacy before and after market entry.
The authority’s multifaceted approach addresses diverse product categories across South Africa’s healthcare landscape. By maintaining continuous quality standards enforcement and adverse event monitoring, SAHPRA demonstrates its commitment to detecting and responding to emerging safety signals in real-world clinical practice. This integrated regulatory model represents a significant advancement in protecting healthcare consumers and maintaining public confidence in the safety of available therapeutic products.
Read the full article on GMJ Newsroom.
Was this article helpful?
